Seroxo is a clinical-stage IVD company developing a proprietary point-of-care (POC) platform technology that enables rapid measurement of Immune Dysfunction, with applications in sepsis, cancer, and organ transplantation. With a clinical data package from 10x clinical trials in over 600 patients, Seroxo has demonstrated the superior performance and clinical benefit of its proprietary biomarker over competing biomarkers. Seroxo anticipates multiple licensing opportunities.
The Leukocyte ImmunoTest™ (LIT™), Seroxo’s finger-prick POC blood test assesses real-time neutrophil function through a patented 10-minute assay that has been shown to be superior to current biomarkers for a range of clinical applications, including sepsis, cancer, and organ perfusion/transplantation. Both clinical and home-use tests will be developed and launched in multiple territories worldwide.
Company Details
- Founded
- -
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.seroxo.com
- Keywords
- Chemical Manufacturing.
- HQ
- London
Seroxo Questions
Seroxo's website is http://www.seroxo.com
Seroxo's LinkedIn profile is https://www.linkedin.com/company/seroxo
Seroxo's industry is
Biotechnology Research
Seroxo's top competitors are
Theracryf,
Algipharma As,
Elasmogen Ltd,
Oxford Medistress Ltd,
Avionova,
Resilient Medical Corp,
Option Tape Specialties,
Primevax Immuno-Oncology,
Ultimovacs Asa,
Nadeno Nanoscience As.
Seroxo's categories are Biotechnology Research
Seroxo's founding year is 2020
